CLINICAL TRIAL SUMMARY

MDACC Study No:2008-0794 (clinicaltrials.gov NCT No: NCT01038388)
Title:A Phase I Trial Evaluating the Safety and Efficacy of Vorinostat (Zolinza) + RVD (lenalidomide{Revlimid}+Bortezomib{Velcade}+Dexamethasone) for Patients with Newly Diagnosed Multiple Myeloma
Principal Investigator:Jatin J. Shah
Treatment Agent:Bortezomib; Dexamethasone; Revlimid; Vorinostat
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of Zolinza (vorinostat) that can be given in combination with Velcade
(bortezomib), Revlimid (lenalidomide), and dexamethasone to patients with MM.
The safety of this drug combination will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I
Treatment Agents:Bortezomib
Dexamethasone
Revlimid
Vorinostat
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:NA
Supported By:Celgene
Merck
Return Visit:Every 3 weeks for routine 8 cycles then every 4 weeks as long as responding to
treatment so it could be as few as 2 and unlimited as long as on therapy.

Home Care:N/A


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jatin J. Shah
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults